<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Clinically relevant photodynamic therapy</segment>
<segment id="3" parent="2" relname="restatement">( PDT )</segment>
<segment id="4" parent="1003" relname="same_unit">was introduced about 45 years ago as a novel means</segment>
<segment id="5" parent="1003" relname="elaboration">for selectively eradicating a variety of solid tumors via cytotoxic photochemistry .</segment>
<segment id="6" parent="1006" relname="same_unit">As an anti-tumor modality , PDT is unique</segment>
<segment id="7" parent="1008" relname="preparation">in requiring three components :</segment>
<segment id="8" parent="1009" relname="span">a photosensitizing agent</segment>
<segment id="9" parent="8" relname="elaboration">( PS ) ,</segment>
<segment id="10" parent="1008" relname="same_unit">PS-exciting light in the far-visible-to-near-infrared range , and molecular oxygen .</segment>
<segment id="11" parent="1012" relname="span">PS photoexcitation during PDT gives rise to cytotoxic reactive oxygen species</segment>
<segment id="12" parent="11" relname="restatement">( ROS )</segment>
<segment id="13" parent="1013" relname="span">such as singlet oxygen</segment>
<segment id="14" parent="13" relname="restatement">( 1O2 ) .</segment>
<segment id="15" parent="1016" relname="span">The first PS</segment>
<segment id="16" parent="15" relname="elaboration">to receive FDA approval for PDT applications</segment>
<segment id="17" parent="1017" relname="span">was Photofrin® , an oligomeric form of hematoporphyrin</segment>
<segment id="18" parent="17" relname="elaboration">that continues to be used for a variety of malignancies .</segment>
<segment id="19" parent="1019" relname="span">Unlike more conventional chemotherapy or radiotherapy ,</segment>
<segment id="20" parent="1021" relname="span">PDT has few</segment>
<segment id="21" parent="20" relname="elaboration">( if any )</segment>
<segment id="22" parent="1022" relname="joint">light-independent side effects</segment>
<segment id="23" parent="1023" relname="joint">and is non-invasive and site-specific ,</segment>
<segment id="24" parent="1024" relname="span">i.e. , limited to the tumor</segment>
<segment id="25" parent="24" relname="elaboration">upon which light is directed , typically via fiber optic networks .</segment>
<segment id="26" parent="1026" relname="span">Moreover , PDT can often overcome the innate or acquired resistance to other therapies</segment>
<segment id="27" parent="26" relname="elaboration">that many tumors exhibit .</segment>
<segment id="28" parent="1027" relname="joint">In addition to pre-existing administered sensitizers such as Photofrin® , pro-sensitizers have been developed ,</segment>
<segment id="29" parent="1029" relname="span">one common example being 5-aminolevulinic acid</segment>
<segment id="30" parent="29" relname="elaboration">( ALA ) .</segment>
<segment id="31" parent="1031" relname="span">Upon entering cancer cells via an amino acid transporter ,</segment>
<segment id="32" parent="1033" relname="span">ALA is metabolized to protoporphyrin IX</segment>
<segment id="33" parent="32" relname="elaboration">( PpIX ) ,</segment>
<segment id="34" parent="1034" relname="span">the active PS , via the heme biosynthetic pathway ,</segment>
<segment id="35" parent="34" relname="elaboration">PpIX accumulating initially in mitochondria .</segment>
<segment id="36" parent="1035" relname="joint">For rapid proliferative needs ,</segment>
<segment id="37" parent="1036" relname="joint">tumor cells are more active in heme synthesis than normal counterparts .</segment>
<segment id="38" parent="1039" relname="background">In addition to acting as a PDT sensitizer ,</segment>
<segment id="39" parent="1039" relname="span">ALA-induced PpIX , like that</segment>
<segment id="40" parent="39" relname="elaboration">induced by more lipophilic ALA esters , e.g. , Hexvix , can serve as a highly effective fluorophore for image-guided tumor resection .</segment>
<segment id="41" parent="1041" relname="joint">Many cancer cells exhibit an intrinsic or acquired resistance to radiotherapy or chemotherapy ,</segment>
<segment id="42" parent="1041" relname="joint">and resistance to PDT has also been demonstrated .</segment>
<segment id="43" parent="1042" relname="joint">For ALA-PDT , one notable resistance mechanism involves efflux of newly synthesized PpIX via the plasma membrane transporter ABCG2 .</segment>
<segment id="44" parent="1046" relname="span">Another important mechanism involves nitric oxide</segment>
<segment id="45" parent="44" relname="restatement">( NO )</segment>
<segment id="46" parent="1046" relname="elaboration">generated by constitutive and/or PDT stress-upregulated inducible nitric oxide synthase</segment>
<segment id="47" parent="1045" relname="elaboration">( iNOS/NOS2 ) .</segment>
<segment id="48" parent="1050" relname="span">NO is a bioactive free radical molecule</segment>
<segment id="49" parent="48" relname="restatement">( 1 – 2 sec lifetime in water )</segment>
<segment id="50" parent="1050" relname="elaboration">that diffuses freely on its own</segment>
<segment id="51" parent="1052" relname="span">and , similar to oxygen</segment>
<segment id="52" parent="51" relname="elaboration">( O2 ) ,</segment>
<segment id="53" parent="1051" relname="same_unit">tends to partition into hydrophobic regions of cells , e.g. , cell membranes .</segment>
<segment id="54" parent="1055" relname="span">At relatively low steady state levels</segment>
<segment id="55" parent="54" relname="elaboration">( e.g. , 50 – 300 nM range ) ,</segment>
<segment id="56" parent="1054" relname="same_unit">NO is known to play a key signaling role in survival , migration , and drug resistance of many different cancer cells .</segment>
<segment id="57" parent="1059" relname="span">This contrasts with the cytotoxic effects of NO</segment>
<segment id="58" parent="57" relname="elaboration">produced at much higher levels</segment>
<segment id="59" parent="1059" relname="restatement">( ≥1 µM )</segment>
<segment id="60" parent="1058" relname="means">by activated macrophages during an inflammatory response , e.g. , to infection .</segment>
<segment id="61" parent="1062" relname="attribution">In previous work , we discovered</segment>
<segment id="62" parent="1062" relname="span">that various cancer cell lines significantly upregulate cytoprotective iNOS and NO after a moderate photodynamic challenge</segment>
<segment id="63" parent="62" relname="elaboration">sensitized by ALA-induced PpIX .</segment>
<segment id="64" parent="1065" relname="span">The iNOS/NO induction in PDT-surviving</segment>
<segment id="65" parent="64" relname="elaboration">( still attached ) cells</segment>
<segment id="66" parent="1067" relname="span">was relatively rapid after irradiation</segment>
<segment id="67" parent="66" relname="restatement">( 2 – 3 h )</segment>
<segment id="68" parent="1068" relname="span">and prolonged</segment>
<segment id="69" parent="68" relname="elaboration">( at least 24 h ) .</segment>
<segment id="70" parent="1069" relname="joint">Importantly , these cells exhibited a more aggressive growth , migratory , and invasive phenotype than non-photostressed controls ,</segment>
<segment id="71" parent="1070" relname="joint">and this was suppressed by inhibition of iNOS or by NO scavenging .</segment>
<segment id="72" parent="73" relname="attribution">We postulated</segment>
<segment id="73" parent="1072" relname="span">that induced diffusible NO from PDT-targeted cells might elicit a pro-growth/migratory response in non- or minimally-targeted bystander cells .</segment>
<segment id="74" parent="1074" relname="span">In an actual tumor , such targeting diversity might result from uneven PS distribution</segment>
<segment id="75" parent="74" relname="cause">due to irregularities in the tumor microvasculature .</segment>
<segment id="76" parent="77" relname="condition">Using photosensitized prostate cancer PC3 cells ,</segment>
<segment id="77" parent="1076" relname="span">we recently observed NO-mediated hyper-aggressive bystander effects for the first time in the context of PDT .</segment>
<segment id="78" parent="1077" relname="span">In the present study , we compared the ability of four PDT-treated cancer lines</segment>
<segment id="79" parent="1078" relname="span">( melanoma BLM , glioblastoma U87 , breast MDA-MB-231 , and prostate PC3 )</segment>
<segment id="80" parent="79" relname="purpose">to stimulate NO-dependent aggressiveness in bystander cells of the same type .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1006" type="multinuc" parent="1001" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1008" type="multinuc" parent="1007" relname="span"/>
<group id="1009" type="span" parent="1008" relname="same_unit"/>
<group id="1010" type="span" parent="1001" relname="joint"/>
<group id="1011" type="multinuc" parent="1010" relname="span"/>
<group id="1012" type="span" parent="1011" relname="same_unit"/>
<group id="1013" type="span" parent="1011" relname="same_unit"/>
<group id="1014" type="multinuc" parent="1011" relname="elaboration"/>
<group id="1015" type="multinuc" parent="1014" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="same_unit"/>
<group id="1017" type="span" parent="1015" relname="same_unit"/>
<group id="1018" type="multinuc" parent="1014" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="joint"/>
<group id="1020" type="multinuc" parent="19" relname="elaboration"/>
<group id="1021" type="span" parent="1020" relname="same_unit"/>
<group id="1022" type="multinuc" parent="1020" relname="same_unit"/>
<group id="1023" type="multinuc" parent="1022" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="joint"/>
<group id="1025" type="multinuc" parent="1018" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="multinuc" parent="1025" relname="joint"/>
<group id="1028" type="multinuc" parent="1027" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1028" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="31" relname="elaboration"/>
<group id="1033" type="span" parent="1032" relname="same_unit"/>
<group id="1034" type="span" parent="1032" relname="same_unit"/>
<group id="1035" type="multinuc" parent="1030" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="joint"/>
<group id="1037" type="multinuc" parent="1036" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="span"/>
<group id="1040" type="multinuc" parent="1037" relname="joint"/>
<group id="1041" type="multinuc" parent="1040" relname="joint"/>
<group id="1042" type="multinuc" parent="1040" relname="joint"/>
<group id="1043" type="multinuc" parent="1042" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="span"/>
<group id="1047" type="multinuc" parent="1043" relname="joint"/>
<group id="1048" type="multinuc" parent="1047" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="span"/>
<group id="1051" type="multinuc" parent="1048" relname="joint"/>
<group id="1052" type="span" parent="1051" relname="same_unit"/>
<group id="1053" type="multinuc" parent="1047" relname="joint"/>
<group id="1054" type="multinuc" parent="1053" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="same_unit"/>
<group id="1056" type="multinuc" parent="1053" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="joint"/>
<group id="1058" type="span" parent="1057" relname="span"/>
<group id="1059" type="span" parent="1058" relname="span"/>
<group id="1060" type="multinuc" parent="1056" relname="joint"/>
<group id="1061" type="span" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="span"/>
<group id="1063" type="multinuc" parent="1060" relname="joint"/>
<group id="1064" type="multinuc" parent="1063" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="same_unit"/>
<group id="1066" type="multinuc" parent="1064" relname="same_unit"/>
<group id="1067" type="span" parent="1066" relname="same_unit"/>
<group id="1068" type="span" parent="1066" relname="same_unit"/>
<group id="1069" type="multinuc" parent="1063" relname="joint"/>
<group id="1070" type="multinuc" parent="1069" relname="joint"/>
<group id="1071" type="multinuc" parent="1070" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="multinuc" parent="1071" relname="joint"/>
<group id="1074" type="span" parent="1073" relname="joint"/>
<group id="1075" type="multinuc" parent="1073" relname="joint"/>
<group id="1076" type="span" parent="1075" relname="joint"/>
<group id="1077" type="span" parent="1075" relname="joint"/>
<group id="1078" type="span" parent="78" relname="elaboration"/>
	</body>
</rst>
